ANI Pharmaceuticals reported 2025 revenue growth of over 39% year-over-year, driven by expanding product portfolios in both generics and branded segments. For fiscal 2026, management projects total revenues between $1.055 billion and $1.115 billion, representing roughly 60% growth compared with 2025. This guidance underscores strong commercial momentum and reflects continued market uptake of recent launches as well as price stability in core generic franchises.

The company’s strategic transformation into a rare disease specialist remains on track, with the rare disease business expected to contribute approximately 60% of 2026 revenues. Purified Cortrophin Gel, the lead asset, is forecast to generate between $540 million and $575 million next year. Management highlighted a planned 90-person expansion of the dedicated sales force and the initiation of a pivotal Phase 4 trial, which is designed to support label enhancements and drive durable, multiyear revenue growth.

ANI’s generics operations delivered robust cash generation in 2025, underpinned by in-house R&D capabilities and U.S. manufacturing efficiencies. The company exited the year with $285 million in cash and short-term investments and expects no net cash burn in 2026. At the current consensus forward P/E of 11.2x, the stock trades at a 43% discount to the peer group average, offering a compelling entry point for investors seeking growth exposure with a solid balance sheet and clear pathway to earnings expansion.